May 7 2010
MMI-USA, a subsidiary of Memometal Technologies S.A., France, a global leader in the manufacture and development of extremity orthopedics, announced today the expansion of its U.S. and worldwide patent and trademark programs. Memometal recognizes the value of its intellectual property and is committed to protecting its products through aggressive procurement and enforcement of patent and trademark rights.
“Because our products have been so successful both commercially and clinically, they are often the subject of copy attempts.”
In addition to its current patents, Memometal has other pending patent applications including United States Patent Application No. 2008/0177262 directed to the Smart Toe® intramedullary implant and a United States Patent Application corresponding to WIPO Publication No. WO 2008/129214 directed to the X-Fuse® intramedullary implant. The company also recently acquired the patent and trademark rights in the United States for OrthoGlide® ankle implants.
"Our goal is to bring new products to the market that improve the surgeon's clinical practice and most importantly, patient outcomes," says Bernard Prandi, Memometal Technologies' co-founder. "Because our products have been so successful both commercially and clinically, they are often the subject of copy attempts."
Memometal intends to take immediate enforcement action. Legal counsel, Norris, McLaughlin & Marcus, PA has been retained to investigate and pursue these false claims.
"Strict patent and trademark enforcement are not only important to our business and industry, but to the surgeons and patients who rely on the quality and efficacy of our products," says Prandi.
The company continues research and development on its rich new product pipeline, as well as on improving existing implant designs, which will form the basis for the future patent filings.